Eisai to Adopt Tiered Royalty Model Instead of Shared Profits/Losses With Biogen for Aduhelm

Eisai has given up its rights to share profits and losses with Biogen on the controversial Alzheimer’s drug Aduhelm (aducanumab-avwa), which the companies developed together. Instead, Eisai will get tiered royalties on net sales beginning Jan. 1, 2023.

Eisai will receive royalties starting at 2 percent and reaching 8 percent when annual sales of Aduhelm exceed $1 billion. And Biogen will now have sole commercialization rights regarding Aduhelm.

The FDA approved Aduhelm last summer even though one of its phase 3 trials didn't show a patient benefit and a panel of FDA advisers voted against the drug. Late last year, Biogen announced that it was dropping the yearly price of Aduhelm by half to $28,200.